All In Biotech

Drug Trial Radar · NCT03263507

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Donidalorsen (IONIS-PKK-LRx) Administered Subcutaneously to Healthy Volunteers

A Double-Blind, Placebo-Controlled, Dose-Escalation Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 721744, an Antisense Oligonucleotide Inhibitor of PKK, Administered Subcutaneously to Healthy Volunteers

Last checked: Nov 20, 2026Latest source record: Aug 4, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

32

Actual

Start

Aug 28, 2017

Primary completion

Oct 9, 2018

Study completion Oct 9, 2018

Sponsor

Lead sponsor
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
Sponsor type
Industry
First posted
Aug 28, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose is to assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Donidalorsen administered subcutaneously to Healthy Volunteers

Conditions

  • Healthy Volunteers

Interventions

  • PlaceboDrug

    Saline .9%

  • DonidalorsenDrug

    Donidalorsen administered subcutaneously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of adverse events that are related to treatment with DonidalorsenTime frame: Up to 176 days
  2. Peak plasma Concentration (Cmax) of DonidalorsenTime frame: Up to 176 days
  3. Time to peak plasma Concentration (Tmax) of DonidalorsenTime frame: Up to 176 days
  4. Effects of Donidalorsen on plasma PKK concentrationTime frame: Up to 176 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ionis Investigative Site

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.